文献速递冠心病外科

Del Nido心脏停搏液在成人单纯冠状动脉旁路移植术中的应用

Del Nido cardioplegia in isolated adult coronary artery bypass surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2019-09-24

本研究回顾性比较了851例成人单纯CABG术中分别使用Del Nido心脏停搏液(DC,n=501)与血性心脏停搏液(BC,n=350)的效果,经倾向性匹配形成325对。结果显示DC组术后肌钙蛋白T中位数更低,但房颤发生率更高,两组四年生存无差异,提示DC在常规及高危患者中非劣效。

要点

  • DC组83%(417/501)采用单次给药,术后肌钙蛋白T中位数低于BC组。
  • DC组房颤发生率33%高于BC组23%(P=.01),其余围术期结局相似。
  • 高龄、低射血分数、左主干病变或STS评分≥2.5%亚组中DC与BC效果相当。

核心结论

  • 在成人单纯CABG中,DC与BC相比心肌保护及临床结局非劣效,常规和高危患者均如此。
  • DC单次给药在单纯CABG中可行,但需更大规模随机研究进一步评估长时间阻断下的安全性。

研究设计与样本

  • 临床数据来自本地胸外科医师协会数据库,死亡数据来自密歇根州社会保障死亡索引。

主要发现

  • DC组单次给药比例为83%(417/501)。
  • 倾向匹配后,DC组术后肌钙蛋白T中位数0.28(0.16-0.59)ng/mL低于BC组0.46(0.27-0.81)ng/mL(P<.01)。
  • 术后超声心动图射血分数BC组54±12%、DC组53±13%(P=.36),无差异。
  • DC组房颤发生率33%高于BC组23%(P=.01),其余围术期结局相似。
  • 亚组分析显示年龄≥75岁、LVEF≤35%、左主干病变或STS评分≥2.5%的患者中,DC与BC心肌保护和临床结局相当。

临床怎么用

  • 成人单纯CABG可考虑使用DC,尤其适合需要单次给药的场景。
  • 使用DC时需关注房颤风险增加,加强术后心律监测。
  • 在高龄、低射血分数、左主干病变或STS评分≥2.5%的高危患者中,DC可作为BC的替代选择。

局限性

  • 回顾性单中心研究,DC与BC使用时间段不同,存在时间偏倚。
  • 仅由2名术者完成手术,结果外推需谨慎。
  • 缺乏长时间阻断亚组的详细安全性数据,需更大规模随机研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Del Nido cardioplegia (DC) offers prolonged single-dose myocardial protection in pediatric cardiac surgery. We set out to evaluate the efficacy of DC in adult patients undergoing isolated coronary artery bypass grafting (CABG). METHODS: From January 2012 to October 2017, 851 consecutive isolated CABG surgeries were performed by 2 study surgeons at our center with blood cardioplegia (BC, n = 350), used from January 2012 to April 2014, and DC (n = 501), used from May 2014 to October 2017. Propensity matching was used to yield 325 well-matched pairs. Clinical data were extracted from our local Society of Thoracic Surgeons database and mortality data from the Michigan State Social Security Death Index. RESULTS: Single-dose administration was used in 83% (417/501) of patients receiving DC. In propensity-matched groups, postoperative median troponin T levels (0.28 [0.16-0.59] ng/mL vs 0.46 [0.27-0.81] ng/mL; P < .01) were lower for patients receiving DC, and no difference in ejection fraction on postoperative echocardiography was observed (54 ± 12% and 53 ± 13% for BC and DC, respectively; P = .36). Perioperative outcomes were similar except for greater rate of atrial fibrillation (33% vs 23%; P = .01) in the DC group. Subgroup analyses revealed equivalent myocardial protection and clinical outcomes in patients with age ≥75 years, left ventricular ejection fraction ≤35%, left main disease, or Society of Thoracic Surgeons score ≥2.5%. Four-year survival did not differ between patients undergoing BC or DC. CONCLUSIONS: The current study revealed noninferior myocardial protection and clinical outcomes with DC versus BC in both routine and greater-risk patients undergoing isolated CABG. DC demonstrated the feasibility of single-dose administration for isolated CABG surgery. Larger randomized studies are needed to further explore the safety and efficacy of DC in adult cardiac surgery with longer crossclamp times.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Timek TA, Beute T, Robinson JA, et al. Del Nido cardioplegia in isolated adult coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2019. PMID: 31706553. doi:10.1016/j.jtcvs.2019.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。